Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial Meeting Abstract
| Authors: | Attard, G.; Sandhu, S. K.; Rathkopf, D.; Castro, E.; Saad, M.; Smith, M. R.; Small, E. J. J.; Olmos, D.; Gomes, A. J. P. D. S; Roubaud, G.; Zurawski, B.; Efstathiou, E.; Wu, D.; Diorio, B.; Urtishak, K.; Singh, U.; Xu, Y.; Lopez-Gitlitz, A.; del Corral, A.; Chi, K. N. N. |
| Abstract Title: | Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S976 |
| End Page: | S977 |
| Language: | English |
| ACCESSION: | WOS:001087480202474 |
| DOI: | 10.1016/j.annonc.2023.09.2754 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1806P -- Source: Wos |
